GlassScriptPhysician profile
Brian James Rogers
NPI 1780796805
$4,026.81
in general payments reported to CMS, 2019-2025
32 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $143 · 2021: $752 · 2022: $1,609 · 2023: $429 · 2024: $476 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $1,095.89 | 2022 | |
| Abbvie INC. | $716.83 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Celularity INC. | $300.00 | 2021 | |
| Exeltis, USA INC. | $227.43 | 2019-2025 | Slynd |
| Evofem Biosciences, INC. | $222.21 | 2020-2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $217.91 | 2019-2024 | Acessa Provu System, Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $188.92 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.02 | 2019-2023 | |
| Sage Therapeutics, LLC | $99.58 | 2024 | |
| Sumitomo Pharma America, INC. | $86.71 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $85.84 | 2021-2025 | Injectafer |
| Astellas Pharma US INC | $78.95 | 2019-2023 | Veozah |
| Therapeuticsmd, INC. | $69.41 | 2019-2021 | |
| Organon LLC | $61.30 | 2022-2025 | Nexplanon, Nuvaring |
| Amgen INC. | $56.22 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $54.03 | 2022 | |
| Pfizer INC. | $50.10 | 2019-2023 | |
| Myovant Sciences INC. | $46.42 | 2022 | |
| Coopersurgical, INC. | $36.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $30.72 | 2019-2025 | Bridion |
| Millicent US INC | $24.09 | 2019-2020 | |
| Mimedx Group, INC. | $21.28 | 2025 | |
| Channel Medsystems, INC. | $16.30 | 2024 | |
| Medtronic, INC. | $16.10 | 2022 | |
| Duchesnay USA Incorporated | $15.74 | 2019 | |
| Allergan, INC. | $15.23 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.00 | 2019 | |
| Lupin INC. | $14.87 | 2019 | |
| Alydia Health | $14.02 | 2021 | |
| Agile Therapeutics, INC. | $13.49 | 2021 | |
| Avion Pharmaceuticals | $12.90 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.